• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

      Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

      CRISPR Combined with Glowing Proteins for Viral Detection

      CRISPR Combined with Glowing Proteins for Viral Detection

      Biomimetic Construct Models Burn Injuries

      Biomimetic Construct Models Burn Injuries

      Moving Cells Using Ultrasound

      Moving Cells Using Ultrasound

    • Radiology
      Imaging Technique Reveals Contraction Patterns During Labor

      Imaging Technique Reveals Contraction Patterns During Labor

      Moving Cells Using Ultrasound

      Moving Cells Using Ultrasound

      Ultrasound Catheter to Treat Hypertension

      Ultrasound Catheter to Treat Hypertension

      Antibacterial Smart Sutures Visible in CT Scans

      Antibacterial Smart Sutures Visible in CT Scans

    • Cardiology
      Scientists Grow Electrodes Inside The Body

      Scientists Grow Electrodes Inside The Body

      Patient-Specific Soft Robotic Heart Replicas for Treatment Planning

      Patient-Specific Soft Robotic Heart Replicas for Treatment Planning

      Tiny Patch for Cardiac Ultrasound Imaging

      Tiny Patch for Cardiac Ultrasound Imaging

      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

    • Surgery
      Biomimetic Construct Models Burn Injuries

      Biomimetic Construct Models Burn Injuries

      Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

      Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

      Self-Assembling Peptides as a Bioink

      Self-Assembling Peptides as a Bioink

      3D Bioengineered Skin Grafts Fit Complex Anatomy

      3D Bioengineered Skin Grafts Fit Complex Anatomy

    • Nanomedicine
      Bottlebrush Particle for Synergistic Drug Combinations

      Bottlebrush Particle for Synergistic Drug Combinations

      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

      Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

HART: From Lab Hardware to Implantable Organs (INTERVIEW)

August 12th, 2014 Michael Batista Exclusive

HARTExpanding a company into a new field of science seems like a daunting challenge. However, Harvard Biosciences (HB) did just that when they aggressively took advantage of an opportunity in regenerative medicine to drive company growth, eventually spinning off Harvard Apparatus Regenerative Technology (HART) in the process. We had a chance to speak with David Green, HART’s current President and CEO and HB’s former President and CEO, about the shift from tissue preservation to tissue regeneration.

Michael Batista, Medgadget:  What path did you take that brought you to running a biomedical company?

D.GreenDavid Green: I’m British by birth and a scientist by training with a physics degree from Oxford. When I went into business I began in brand management at Unilever, which proved to be a great training ground. I decided to expand my business education by attending Harvard Business School. Afterwards, looking to work in a field related to my degree, I worked at Monitor, a Harvard spin-off started by Michael Porter. At Monitor, we focused on corporate strategy consulting to help big companies grow and become more profitable. An exciting part of that work was ending up in Johannesburg, South Africa for two years consulting on industrial policy during the Mandela elections.

After I returned to the US, I began working with HB. I grew the company and ultimately took it public in 2000. HB focuses on making lab equipment for isolated organ research (a niche within a niche). This allows organs to remain alive outside the body for pharmaceutical companies to test drugs.

 

Medgadget: What happened at HB that made the company start thinking about regenerative medicine?

Mr. Green: In the summer of 2008, Dr. Harold Ott, now at Massachusetts General Hospital, called HB about our product line. However, he asked for the product to be sterile which was initially confusing for us since this wasn’t the typical use case at the time. What we eventually learned was that he was trying to actually grow organs outside the body for which sterile organ isolation equipment made sense. At the time HB was suffering from low growth and looking for new growth opportunities in the area that eventually became regenerative medicine. We entered into a sponsored research agreement in August 2008 and were on our way to developing bioreactors.

In December of 2008, Professor Paolo Macchiarini published a paper in the Lancet where he described the first clinical transplantation of a tissue-engineered trachea. In the paper he described a bioreactor that he used and built to grow the trachea. We reached out and asked if he was interested in licensing the technology. With this, we were able to then offer a bioreactor product for solid organs (hearts and lungs) and hollow organs (trachea). Of the two, however, only a hollow organ, a trachea, had been implanted in humans.

Keep in mind that HB still did not see itself as a biotechnology company; we were a bioreactor company. At the time scaffolds were also still being reconstituted from dead patients. This was not an ideal approach since natural scaffolds would weaken. Paolo was looking for an alternative solution and began considering synthetic materials.

 

Medgadget: How were the synthetic scaffolds developed and have they been tried in humans?

Mr. Green: Initially, the first generation synthetic scaffolds still had problems. Those scaffolds were too stiff, hard to suture, and were not porous. Paolo had the idea to use more fibrous materials to make the suturing easier and reduce the stiffness. This characterized the second generation scaffolds and is now used in all our products. To make the fibrous material for the trachea scaffolds we used electrospinning. We worked with an academic lab, which became the spinout, Nanofiber Solutions. While working with the group to make the scaffolds, we realized that we couldn’t sell bioreactors without driving the market for the scaffolds to put in them. There was concern that Nanofiber Solutions could not scale up to meet the need and FDA requirements. In late 2012, we decided to take over production of the scaffolds themselves. In April 2013 we received approval to use the scaffold for the first time in a patient born completely without a trachea. It was a last resort solution for that patient and they, unfortunately, did soon die. It was the first time we manufactured both the bioreactor and the scaffold.

 

Medgadget: What factors are important when developing a scaffolding material for tissue regeneration and implant?

Mr. Green: There are four important factors that go into a good scaffold. First, for the scaffold to function well we really need the fibers to be down in the 1 micron range, which is possible with electrospinning. Since the cells need to physically make it onto the scaffold, the fibers need to act like a sieve for the cells in media. Second, certain materials improve cell adhesion to the scaffold. We typically use polyethylene terephthalate (PET) for HART’s scaffolds. Third, the cells have to be able to connect with each other so the scaffold needs to be porous to allow optimal interactions between the cells. Fourth, now that you have a well seeded scaffold, it has to get into the patient where vasculature will grow into the scaffold. Part of the trick here is to get the scaffold to vascularize quickly to get the cells to grow. An old technique that is still used is to use omentum, which is separated from the stomach and relocated up to the neck over the trachea scaffold to provide an immediate blood supply. This also helps the new trachea from collapsing since the neck is constantly in motion through swallowing, coughing, sneezing, etc. A lot of mechanical properties have to be met all while providing a safe haven for cell growth.

 

Medgadget: What about 3D printing organs?

Mr. Green: Our approach is better than 3D printing for a few reasons. There is simply no 3D printer with the resolution we need for the kinds of physical structures the cells are comfortable with. The best resolution you can get is 200 microns. Also, the inks used in 3D printers do not represent the kinds of materials we need our scaffolds made of for optimal cellular interactions. Finally, if you are trying to 3D print biological materials, you are not really making a mechanically robust structure to implant in the body.

 

Medgadget: At what point did HB and HART become differentiated?

Mr. Green: After this first US surgery with our approved products, we had another discussion with the FDA who told us they did not think HB was a medical device company. Instead, they claimed, we were a biological product company since our solutions used cells. To recap we had now gone from lab equipment, to implantable medical devices, to biotechnology. The final change in thinking occurred when we stopped thinking of the implant material as scaffolding and began thinking about it as a tissue.

We began to invest more and more money into this part of the company. The amount of capital began to increase significantly but was beginning to eat into HB’s profits so we made the decision to split the company in two to give what became the new company, HART, sufficient flexibility to function on its own. This happened on November 1, 2013 and since then HART and HB have functioned as two separate companies.

 

Medgadget: Why and how did you grow a company from what is still a very new science?

Mr. Green: One of the big motivators was seeing that a trachea has been done and implanted in humans. Many products have been successfully developed in animals that failed in humans. Having proof that we could get a clinically relevant outcome was a huge benefit and a driver of our focusing in on this area of regenerative medicine.

From a business standpoint, when we began looking at regenerative medicine, we were looking at all the companies in the space and seeing that most were failures. The earliest were skin companies like Organogenesis and Advanced Tissue Sciences, which became Advanced Biohealing. Both went bankrupt and continued as smaller companies after massive layoffs. Looking at these, there was not a lot of business success to raise capital and develop a product. Besides skin companies, bladders were being addressed in some ways where clinicians were opening and enlarging their capacities. Tangeon raised and went public but had a tiny cap compared to what was put into the company.

Skin, bladder, blood vessels, knee cartilage, they were all working and could be manufactured at scale but no one was making money. We decided the problem with regenerative science was not the technology but the business. In order to drive sales, the solutions had to have a high value (i.e. be lifesaving) and couldn’t have an easy, cheap alternative. For example, companies are developing blood vessels for heart bypass. However, while this seems like a high medical value, the clinician can get the material to perform this surgery for free from the legs of the patient. We needed to focus on a life threatening indication that could be solved with a tissue engineering or regenerative medicine approach. The trachea was a great option because it is life threatening and had already been shown to be viable in humans.

 

Medgadget: What is the status of HART’s current clinical studies?

Mr. Green: We have an ongoing clinical trial in Russia and have received a grant to begin a trial in the EU. The Russian clinical trial began over a year ago with five patients implanted. The 6 month follow up was presented at the European Society of Thoracic Surgeons. The patients are doing well but Nanofiber Solutions made the scaffolds, so they are weaker and beginning to narrow in the patients’ necks. This is what partly led
to the impetus to make our own scaffold products. We do expect to have US hospitals as part of a clinical trial. That trial is projected to be completed by 2017.

 

Medgadget: What other organs can benefit from HART’s approach?

Mr. Green: The next organ to be transplanted in humans will probably be the esophagus due to the technical similarities between it and the trachea. Like the trachea it is a hollow and is transplanted by the same type of surgeons who would perform the trachea operations. A few months ago a paper published by Paolo discussed the regeneration and transplant of an esophagus in a rat.

 

Medgadget: What are your thoughts on the future of regenerative medicine for more complex organs and tissues?

Mr. Green: Soft tissues and other soft materials are very accessible to printing solutions. It gets a bit more challenging when we think of structures with more variations and multiple different cell types and components: muscle cells, nerves, blood vessels, collagens. It is hard to believe that printing cells will be the right solution for complex organs like the heart. Something incorporating a hybrid of various fabrication technologies seems more plausible at this time.

divider

Link: Harvard Apparatus Regenerative Technology…

 

Michael Batista

Michael Batista is a Baltimore-based editor motivated by disruptive innovation at the intersection of technology and healthcare. He holds a dual B.S. in materials and bioengineering from MIT and an M.S. in biomedical engineering from Johns Hopkins. Michael is currently Director of Healthworx, CareFirst BCBS' corporate development, and commercialization team. Michael is the former CEO of digital health startup Quantified Care through its exit to CollabCare and runs a board game publishing company.

Sponsored
Venture builder BHV Partners launches Conus Airway to improve anaesthesia  and respiratory surgery

Venture builder BHV Partners launches Conus Airway to improve anaesthesia and respiratory surgery

FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management

FDA Expands Indications for Use of FibroScan® for Comprehensive Liver Management

machineMD and Varjo revolutionize the diagnosis of brain disorders with a VR-based eye-tracking solution 

machineMD and Varjo revolutionize the diagnosis of brain disorders with a VR-based eye-tracking solution 

Ax-Surgi Hemostat gets FDA Clearance for Surgical Bleeding Control

Ax-Surgi Hemostat gets FDA Clearance for Surgical Bleeding Control

Clarius Report Finds 85% of Clinicians Believe Ultrasound Leads to Better Patient Outcomes

Clarius Report Finds 85% of Clinicians Believe Ultrasound Leads to Better Patient Outcomes

interviews & reviews
Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

Levels Is Making Metabolism and Blood Glucose Tracking Accessible To Everyone

Imagene Profiles Cancer Biomarkers in Real Time

Imagene Profiles Cancer Biomarkers in Real Time

Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

Empowering Stroke Survivors: Interview with Kirsten Carroll, CEO at Kandu Health

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Neuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical

Neuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email